|Immunotherapy in Glioblastoma.
|Year of Publication
|Wilcox JA, Ramakrishna R, Magge R
|Antibodies, Monoclonal, Combined Modality Therapy, Dendritic Cells, Glioblastoma, Humans, Immunotherapy, T-Lymphocytes
Glioblastoma evades conventional therapies through a variety of mechanisms, including suppression of the immune system. This immunosuppressive microenvironment provides a potential target for treatment. There are several immunotherapies being actively investigated, including inhibition of immune checkpoint regulators, development of antitumor vaccinations from both dendritic cell and tumor peptide components, adoptive transfer of supercharged and durable T lymphocytes, and generation of oncolytic viruses. Although immunotherapy has already demonstrated efficacy for a variety of other malignancies, its efficacy in glioblastoma is still unclear. Identifying predictive biomarkers and improving the management of immune-related adverse effects will help to realize the full potential of these therapies.